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Abstract
Over the past decade a large body of evidence has accumulated implicating defects of human mitochondrial DNA in the
pathogenesis of a group of disorders known collectively as the mitochondrial encephalomyopathies. Although impaired
oxidative phosphorylation is likely to represent the final common pathway leading to cellular dysfunction in these diseases,
fundamental issues still remain elusive. Perhaps the most challenging of these is to understand the mechanisms which underlie
the complex relationship between genotype and phenotype. Here we examine this relationship and discuss some of the factors
which are likely to be involved. ß 1999 Elsevier Science B.V. All rights reserved.
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1. Introduction
The mitochondrial encephalomyopathies are a het-
erogeneous group of diseases which are mostly
caused by inborn errors of oxidative phosphorylation
(reviewed in [1^4]). Despite the wide range of clinical
presentations, a number of distinctive syndromes
have been identi¢ed. The most notable of these
are: (1) progressive external ophthalmoplegia
(PEO) and the Kearns-Sayre syndrome (KSS), (2)
mitochondrial encephalomyopathy, lactic acidosis
and strokes (MELAS), (3) myoclonic epilepsy with
ragged-red muscle ¢bres (MERRF), (4) mitochon-
drial neurogastrointestinal encephalomyopathy
(MNGIE), (5) Leigh’s syndrome, and (6) the syn-
drome of neurogenic weakness, ataxia and retinitis
pigmentosa (NARP). In addition to distinctive ence-
phalomyopathies, mutations in oxidative phospho-
rylation genes have been identi¢ed in Leber’s heredi-
tary optic neuropathy (LHON), Pearson’s bone
marrow-pancreas syndrome, diabetes mellitus and
deafness, hypertrophic and dilated cardiomyopathy,
multiple symmetrical lipomatosis, non-syndromic
and aminoglycoside induced sensorineural deafness,
fatal infantile hepatopathy, recurrent myoglobinuria
and other relatively pure myopathies as well as in
various encephalomyopathies and multisystem dis-
eases which lack distinctive features and cannot be
assigned to any of the above categories. Many of
these disorders are maternally inherited but some
are sporadic and others appear to be transmitted
as mendelian traits. Ragged-red muscle ¢bres
(RRF), an established morphological hallmark of
these disorders, are uncommon in Leigh’s syndrome
and in LHON and have not yet been reported in
NARP.
With the exception of defects in Complex II [5],
most of the well characterised inborn errors of oxi-
dative phosphorylation have been linked to muta-
tions in the mitochondrial genome (mtDNA), a
highly compact, double stranded circular molecule
of 16 569 nucleotide pairs which codes for 13 of the
90 or so polypeptide components of this major en-
ergy generating pathway assembled in the mitochon-
drial inner membrane [1^4,6,7]. Various pathogenic
mtDNA abnormalities have been identi¢ed, the com-
monest being large-scale rearrangements (single dele-
tions, multiple deletions, duplications) and point mu-
tations in transfer RNA (tRNA), or protein encoding
genes. Virtually all these disorders are characterised
by mtDNA heteroplasmy in that mutated and wild-
type genomes co-exist in variable proportions and
with tissue-to-tissue and cell-to-cell di¡erences within
the same individual. Whether mtDNA heteroplasmy
extends to the individual mitochondrion is not
known.
Although various cell culture systems have been
used to study the functional consequences of some
of the more common mtDNA mutations [8^16], their
precise roles in disease pathogenesis and the mecha-
nisms which account for observed disparities between
mtDNA genotype and clinical phenotype have not
been resolved. The association of di¡erent syndromes
with the same mutation [17^23] and di¡erent muta-
tions with the same syndrome [24^31] has prompted
speculation that additional mechanisms such as the
genetic background [32^35], immunological [36] or
environmental factors [37], or even the ageing proc-
ess itself [38] maybe important contributory determi-
nants of phenotypic expression.
Here we review the range of disease phenotypes
associated with some of the more common mtDNA
mutations and discuss possible mechanisms which
might account for such remarkable clinical diversity.
2. MtDNA mutations involving protein encoding genes
For reasons which remain unclear, some mtDNA
mutations appear to be relatively speci¢c in their
clinical manifestations, whereas the majority are
not (Tables 1^5). The former situation currently ap-
plies to the primary LHON mutations [38,39] and to
the T8993G transversion in the ATPase 6 subunit
gene originally identi¢ed in NARP [40]. Studies of
additional pedigrees have shown that when the pro-
portion of the NARP 8993 mutation in blood or
muscle exceeds 90% it causes Leigh’s syndrome
[41^43]. Individuals harbouring mutant levels of
70^90% either present with NARP or with varying
degrees of mental subnormality and developmental
delay [43,44]. Levels below 70% are usually asympto-
matic. Atypical features appear to be uncommon,
but stoke-like episodes suggestive of the MELAS
phenotype and PEO have been described [43,45]
and hypertrophic cardiomyopathy was a novel clin-
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ical manifestation in one infant with Leigh’s syn-
drome associated with the T8993G mutation [46].
The T8993G mutation changes a highly conserved
leucine for arginine in the ATPase 6 subunit which is
a component of the proton channel of Complex V.
Studies of cell culture systems virtually homoplasmic
for the NARP mutation have shown V50% reduc-
tion in State III respiration and in the ADP/O ratio
[14] and a similar decrease in the rate of synthesis of
ATP [47].
Four other pathogenic mutations in ATPase 6
have been identi¢ed (Table 1). One of these, a
T8993C transition, has also been associated with
Leigh’s syndrome [31,48]: two further T-to-C transi-
tions at 8851 and 9176 were originally associated
with bilateral striatal necrosis [49,50] and a fourth
at 9101 with LHON [51]. More recently, however,
the T9176C transition has been described in Leigh’s
syndrome [52,53] and in sudden infant death [53].
None of the ATPase 6 mutations identi¢ed to date
has induced signi¢cant mitochondrial proliferation
(RRF) in skeletal muscle, but at an ultrastructural
level abnormal mitochondria with paracrystalline in-
clusions have been observed [45].
The three primary LHON mutations are each as-
sociated with a highly tissue-speci¢c phenotype
which causes subacute and severe visual loss espe-
cially in young adult males [38,39]. The G11778A
transition is by far the commonest and accounts
for over 50% of all cases world-wide. The clinical
features associated with the three primary LHON
mutations are similar except that the chances of
some visual recovery appear to be greater with the
14 484 mutation than with the other two [39]. The
predominance of a¡ected males and the observation
that some males and the majority of females virtually
homoplasmic for one of the LHON mutations never
develop visual loss suggests that the mutation itself is
not the sole determinant of the disease phenotype. A
putative visual-loss susceptibility locus on the X
chromosome has been invoked to explain the male
bias [34] and the occurrence of a multiple sclerosis
Table 1
MtDNA mutations in protein-encoding genes (maternal or sporadic)
Gene Mutation Phenotype Ref.
ND1 T3308C MELAS [27]
G3460A LHON þ MS [38,39]
ND4 A11696G LHON and/or dystonia [55]
G11778A LHON þ MS [38,39]
ND5 G13513A MELAS [26]
ND6 G14459A LHON and/or dystonia [54]
T14484C LHON [38,39]
T14596A LHON and/or dystonia [55]
Cytochrome b G15615A Exercise intolerance [208]
(+D-loop duplication) [209]
COX I 5-bp deletion Motor neuron-like disease [58]
COX III G9952A Recurrent encephalopathy [57]
T9957C MELAS [25]
15-bp deletion(9486^9502) Cramps and myoglobinuria [56]
ATPase 6 T8851C Striatal necrosis [49]
T8993G NARP [40,41,43,45]
NARP and stroke [43,45]
NARP and PEO [45]
Cerebral palsy [44]
Leigh’s syndrome [41^43,45]
Leigh and cardiomyopathy [46]
T8993C Leigh’s syndrome [48]
T9101C LHON [51]
T9176C Striatal necrosis [50]
Leigh’s syndrome [52,53]
Sudden infant death [53]
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(MS)-like illness in some a¡ected females with the
11 778 or 3460 mutations has prompted speculation
that autoimmune mechanism may contribute to dis-
ease pathogenesis [36,39].
In contrast to the primary LHON mutations, al-
lelic mutations in ND1, ND4 and ND6 have been
associated with somewhat di¡erent clinical pheno-
types (Table 1). The G14459A transition in ND6
and the A11696G transition in ND4 have been asso-
ciated with LHON and/or dystonia [54,55] and the
T3308C in ND1 with MELAS [27]. Another point
mutation in a Complex I gene, a G13513A transition
in ND5 has also been associated with the MELAS
phenotype [26].
Similar phenotypic heterogeneity has been ob-
served with allelic mutations in the cytochrome oxi-
dase subunit III (COX III) gene. Of the three
mtDNA abnormalities which have been described
(Table 1), one a T9957C mutation was associated
with MELAS [25] and the other a 5-bp in-frame
microdeletion with muscle cramps and myoglobinu-
ria [56]. The third COX III mutation which intro-
duced a premature stop codon 13 amino acids up-
stream from the C-terminus, was associated with a
unique clinical phenotype characterised by recurrent
episodes of coma with virtually complete recovery
between attacks [57]. Unlike the other two COX III
mutations, the muscle biopsy on this patient lacked
RRF but the majority of the muscle ¢bres showed
markedly reduced COX activity when examined his-
tochemically, a ¢nding which was con¢rmed on bio-
chemical analysis [57]. Recently, a heteroplasmic 5-
bp out-of-frame deletion in the COX I subunit gene
has been identi¢ed in an adult male with a motor
neurone disease-like syndrome, characterised by a
progressive spastic quadraparesis, speech and swal-
lowing di⁄culties and minor lower motor neurone
signs [58]. Muscle histochemistry showed RRF to-
gether with a high proportion of COX de¢cient ¢bres
and an isolated COX de¢ciency was con¢rmed on
biochemical analysis. Immunoblot analysis and im-
munostaining of muscle in each of the two patients
with microdeletions in COX genes showed decreased
immunoreactivity for several COX subunits suggest-
ing impaired assembly or decreased stability of the
holoenzyme [56,58].
3. MtDNA mutations involving tRNA genes
The relatively speci¢c manifestations associated
with the LHON and NARP mutations contrast to
some extent with the phenotypic heterogeneity asso-
ciated with the common MERRF (myoclonic epi-
lepsy with RRF) mutation, an A8344G transition
in the mitochondrial tRNALys gene (Table 2). Most
index cases present with myoclonus and ataxia, the
core clinical features of MERRF, and like NARP
patients they have quite high levels of the mutation
in blood (s 30%); unlike the NARP mutation, how-
ever, levels in muscle and other tissues are usually
much higher (s 70%) [59^61]. Atypical phenotypes
are not uncommon and include PEO, encephalomy-
opathy without myoclonus, encephalomyopathy with
recurrent strokes, multiple symmetrical lipomatosis,
myopathy plus cardiomyopathy or myopathy alone
[22,23,61,62]. Like the NARP mutation, the A8344G
transition has also been associated with Leigh’s syn-
drome [31,63]. Although RRF are invariable in
MERRF they are absent in some atypical cases in-
cluding one patient with Leigh’s syndrome, whose
muscle was virtually homoplasmic for the mutation
[63].
Studies of the e¡ects of the 8344 mutation in cul-
tured myotubes [11] and in cytoplasmic hybrids
[8,64], formed by fusing patient derived cytoplasts
Table 2
MtDNA mutations on the tRNALys gene (maternal or sporadic)
Mutation Phenotype Ref.
G8313A Gastrointestinal dysfunction, seizures,
myoclonus, dementia, ataxia, deafness,
pigmentary retinopathy, axonal
neuropathy
[72]
A8344G MERRF [59^61]
MERRF-MELAS overlap [60^62]
Encephalomyopathy without myoclonus [23,60,61]
PEO, myopathy [23,61]
Myopathy, cardiomyopathy [23]
Myopathy alone [23]
Leigh’s syndrome [31,63]
Multiple symmetrical lipomatosis [22]
T8356C MERRF [30]
MERRF-MELAS overlap [68,69]
G8363A Cardiomyopathy, deafness, ataxia,
ophthalmoparesis
[71]
MERRF [70]
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(enucleated cells) to human cell lines devoid of
mtDNA (b0 cells), have shown that as little as 10%
wild-type mtDNA is su⁄cient to prevent expression
of the mutant phenotype. Below this level there is a
rapid decline in respiratory chain activity and in the
synthesis of mtDNA encoded proteins, especially
those with a high lysine content. In cultured myo-
blasts, however, the translation defect occurs with
lower levels of the mutation [11,15] and in one study
appeared to preferentially a¡ect the synthesis of
COX subunits [15]. Expression of the phenotype
with lower levels of the MERRF 8344 mutation
has also been observed in platelet derived cytoplas-
mic hybrids [65]. The mechanism of these di¡erences
is not known, but could re£ect the much lower copy
number of mtDNA molecules per organelle in myo-
blast and platelet mitochondria. Proteins with altered
electrophoretic mobilities have been observed in cul-
tured myotubes and cybrids harbouring the 8344 mu-
tation, but the e¡ects of these abnormal translation
products on respiratory chain function and assembly
have not been studied. They are thought to arise
from premature termination of translation at or
near lysine codons due to defective aminoacylation
of the mutant MERRF tRNALys by its cognate lysyl-
tRNA synthetase [66]. If 10% wild-type mtDNA is
su⁄cient to rescue myotubes and cybrids, however, it
seems likely that even lower levels may be su⁄cient
in vivo. A notable feature of the common MERRF
mutation is its presence in universally high levels
even in organs which appear to function normally
during life and show no histological abnormality
[23,63]. A similar discrepancy between the propor-
tions of mutant mtDNA and neuronal cell loss has
been observed in di¡erent regions of autopsied
MERRF 8344 brain [67].
Three other pathogenic mutations in the tRNALys
gene have been described (Table 2). A T-to-C tran-
sition at 8356 has been associated with MERRF [30]
and with the MERRF-MELAS overlap [68,69]. A G-
to-A transition at 8363 has also been identi¢ed in
MERRF [70] and in two unrelated families with a
complex multisystem disease characterised by hyper-
trophic cardiomyopathy, sensorineural deafness,
ataxia and PEO without myoclonus [71]. More re-
cently a novel G8313A mutation in the tRNALys
gene has been identi¢ed in a young boy who pre-
sented at the age of four with severe gastrointestinal
dysfunction and pseudo obstruction closely resem-
bling the MNGIE phenotype [72]. He subsequently
went on to develop myoclonus, seizures, progressive
mental regression, cerebellar ataxia, pigmentary ret-
inopathy, deafness and a peripheral axonal neuropa-
thy and died in his mid teens. In vitro studies have
shown that both the 8344 and the 8356 tRNALys
mutations have similar functional consequences and
both lead to the synthesis of abnormal translation
products [64,65,73].
Perhaps the most complex of all the known
mtDNA defects is the common MELAS mutation,
an A3243G transition in the mitochondrial
tRNALeuUUR gene (Table 3). This single base
change in a mitochondrial gene involved in transcrip-
tional control as well as in RNA processing and
translation [74] accounts for over 80% of patients
with MELAS [18,75,76] but it also occurs in sporadic
and maternally inherited syndromes with PEO,
sometimes closely resembling the KSS phenotype
[18,19,75,77,78], and in diabetes mellitus and deaf-
ness [20,79], encephalomyopathies without strokes
[18,19,77] and myopathy alone [18,77], or associated
with recurrent episodes of respiratory failure [21]. In
a large group of unselected patients harbouring the
MELAS 3243 mutation, the majority did not have
the MELAS phenotype [18]. As with the NARP mu-
tation, there appears to be some correlation between
clinical phenotype and the percentage of mutant
mtDNA in muscle which tends to be higher in early
onset cases with typical MELAS than in late onset
MELAS or in patients with other clinical phenotypes
[18,19,77,78].
The precise mechanism of the A3243G transition
in disease pathogenesis remains unknown. In addi-
tion to possibly altering the structure and function of
one of the leucyl tRNAs, the mutation is located
within a tridecamer sequence which binds the tran-
scription termination factor mTERF [80]. The bind-
ing of mTERF at this site normally serves to selec-
tively increase the rate of transcription of the
upstream 12S and 16S rRNA genes (but not the
downstream heavy-strand genes), thereby ensuring
that there are su⁄cient 12S and 16S rRNAs for
the translation of mRNAs encoding all 13 polypep-
tides. Although the binding of mTERF to the
MELAS template was found to be greatly reduced
in vitro [80], there is no evidence that transcription
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termination is impaired in vivo [81], or in cytoplas-
mic hybrids virtually homoplasmic for the MELAS
mutation [10,82]. However, a study of patient de-
rived myoblast clones with 93% of the MELAS
mutation, showed a decreased steady-state amount
of the 16S rRNA when compared with myoblasts
harbouring a deletion of mtDNA which did not in-
volve the transcription termination site, suggesting
that the capacity to enhance upstream transcription
may have been limited by the MELAS mutation [83].
It also remains unclear whether alterations in the
processing of RNA 19, a polycystronic precursor
transcript corresponding to the 16S rRNA+
tRNALeuUUR+ND1 which was found to be in-
creased in MELAS tissues [84], contributes to the
markedly reduced rates of synthesis and steady-state
levels of mtDNA encoded polypeptides observed in
cybrids harbouring s 90% mutant genomes [10,84,
85]. The mtDNA encoded polypeptides with the
highest proportion of leucine (UUR) residues are
the Complex I subunits ND3 and ND6. Although
the functions of these subunits are not known, loss
of ND3, ND6 or both might explain why Complex I
de¢ciency is the commonest respiratory chain defect
in MELAS muscle [77]. In a recent study of cybrid
clones harbouring di¡erent proportions of the
MELAS 3243 mutation, those containing 60% or
more of mutant mtDNAs synthesised little or no
ND6 and showed a defect in Complex I [16]. How-
ever, di¡erent clones harbouring similar levels of mu-
tant mtDNA showed widely di¡ering oxygen con-
sumption rates, and even cybrids with 95% of
mutated mtDNA retained some respiratory capacity
and COX activity.
Of the 11 additional mutations identi¢ed in the
tRNALeuUUR gene, 3 have been associated with
MELAS [28,86,87] and one of these mutations, an
A3260G transition, has also been identi¢ed in two
families with maternally inherited myopathy and car-
diomyopathy [88,89] (Table 3). The remaining
tRNALeuUUR mutations have been associated with
diverse clinical phenotypes [90^100]. Mutations in
12 other mitochondrial tRNA genes and a unique
9-bp insertion into a non-coding sequence of
Table 3
MtDNA mutations in the tRNALeuUUR gene (maternal or sporadic)
Mutation Phenotype Ref.
A3243G MELAS [17,18,75,76,78]
MERRF-MELAS overlap [18,19,75,77]
PEO þ retinopathy and/or deafness [17^19,75,77,78]
KSS [19,78]
Encephalomyopathy without stroke [18,19,77]
Diabetes þ deafness [20,79]
Myopathy [18,77]
Myopathy with respiratory failure [21]
A3243T Encephalomyopathy [90]
T3250C Myopathy with respiratory failure [91]
A3251G PEO, myopathy, psychiatric disordersudden death [92]
A3252G Dementia, retinopathy, diabetes, hypoparathyroidism, paraparesis,
heart block, renal failure
[93]
C3254G Myopathy, cardiomyopathy [94]
C3256T PEO, retinopathy, deafness, seizures, myoclonus, hypothyroidism [95]
Diabetes, myopathy [96]
A3260G Myopathy and cardiomyopathy [88,89]
MELAS [87]
T3271C MELAS [86,97]
Deafness and muscular fatigue [97]
T:A bp deletion (3271^3273) Encephalopathy, endocrinopathybrain calci¢cation (Fahr syndrome) [98]
T3291C MELAS [28]
A3302G Myopathy with respiratory failure [99]
C3303T Cardiomyopathy [100]
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mtDNA have also been linked to human disease
[29,95,101^131]. These are listed together with their
respective phenotypes in Table 4. Three of these mu-
tations have also been associated with MELAS, fur-
ther highlighting the remarkable locus heterogeneity
associated with the MELAS phenotype, which to
date has been linked to at least 11 di¡erent mtDNA
mutations (Tables 1^5 and references therein).
4. Large-scale rearrangements of mtDNA involving
both tRNA and protein encoding genes
The relationship between the mtDNA genotype
and clinical phenotype is no less complex with
large-scale deletions of mtDNA which eliminate
both tRNA genes and open reading frames (Table
5). These rearrangements are commonly found in
sporadic forms of PEO including KSS [132,133], as
well as in Pearson’s syndrome [134], a potential pre-
cursor of KSS [135]. However, deletions alone, or as
part of a family of large-scale mtDNA rearrange-
ments comprising deletion dimers and duplications
as well as deletions [136], have been identi¢ed in
other phenotypes including diabetes mellitus and
deafness [137], the Wolfram syndrome [138], ataxic
leucodystrophy [139], infantile diarrhoea with villous
atrophy [140], MELAS [141], the KSS-MELAS over-
Table 4
MtDNA mutations in other tRNA genes (maternal or sporadic)
Gene Mutation Phenotype Ref.
tRNAPhe A583G MELAS [101]
A606G Acute rhabdomyolysis [102]
tRNAVal G1606A Ataxia, seizures, dementia, deafness, myoclonus, cataract [103]
G1642A MELAS [29,104]
A1644T Adult Leigh’s syndrome [105]
tRNAIle A4269G Encephalopathy, fatal cardiomyopathy [106]
T4274C PEO, myopathy, ataxia [107]
T4285C PEO [108]
A4295G Hypertrophic cardiomyopathy [109]
G4298A PEO+MS [110]
A4300G Hypertrophic cardiomyopathy [111]
A4317G Encephalomyopathy, fatal cardiomyopathy [112]
C4320T Encephalopathy, cardiomyopathy [113]
tRNATrp 5537T insert Optic atrophy, ataxia, dementia [114]
Leigh’s syndrome [114]
G5549A Dementia, deafness, ataxia, chorea [115]
tRNAAsn A5692G PEO, myopathy, ataxia [116]
G5703A PEO [95]
tRNACys A5814G MELAS [117]
tRNASerUCN A7445G Non-syndromic deafness [119]
7472C insert Deafness, ataxia, myoclonus neuropathy [120]
T7512C MERRF-MELAS overlap [118]
tRNAGly T9997C Hypertrophic cardiomyopathy [121]
A10044G Fatal infantile multisystem disease [122]
tRNALeuCUN T12311C PEO [123]
G12315A PEO [123]
A12320G Myopathy [125]
tRNAGlu T14709C Congenital encephalomyopathy [126]
Myopathy and diabetes [127]
tRNAThr G15915A Encephalomyopathy [128]
A15923G Fatal infantile multisystem disease [129]
tRNAPro C15990T Myopathy [130]
9-bp insertion between
COX II and tRNALys
PEO, optic atrophy, ataxia, seizures, deafness, dementia [31]
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lap [142,143], Leigh’s syndrome [31,144] and mi-
graine with recurrent strokes [145]. In patients with
PEO syndromes, there appears to be no clear cut
correlation between the proportion of deleted
mtDNAs in muscle or the site or extent of the dele-
tion and the severity of the clinical phenotype
although some correlation has been demonstrated
with the so-called common deletion [146]. However,
the levels of deleted mtDNAs in di¡erent regions of
the central nervous system (CNS) also correlates
poorly with the clinical features or with the neuro-
pathology, which in KSS resembles that seen in
Leigh’s syndrome [143]. Despite being present in
low abundance in apparently normal mature oocytes
[147], mtDNA deletions are usually sporadic, and
with few possible exceptions [148] are not maternally
transmitted [149]. This is in contrast to mtDNA du-
plications, which can be maternally transmitted
[150,151] possibly because they are less pathogenic
[152].
Studies of cybrids harbouring partially deleted ge-
nomes have shown a similar sharp decline in respi-
ratory chain activity and in the synthesis of mtDNA
encoded proteins, to that seen with the MERRF
8344 and MELAS 3243 mutations, except that the
amount of wild-type mtDNA needed to prevent these
changes is somewhat higher (V40%) [9]. The synthe-
sis of polypeptides of the size predicted for fusion
proteins in cybrid clones harbouring a deletion which
eliminated ¢ve tRNA genes indicated that the miss-
ing tRNAs were being transcribed from wild-type
genomes. When the level of deleted mtDNAs ex-
ceeded V61%, however, evidence for translational
complementation was not observed [9].
5. Defects of mtDNA attributed to nuclear gene
mutations
Multiple deletions of mtDNA are either sporadic
[153,154] or appear to be inherited as mendelian
traits, suggesting that the primary genetic errors re-
side in nuclear genes [155]. Like most other mtDNA
abnormalities, they have been identi¢ed in a variety
of di¡erent phenotypes including sporadic, autoso-
mal dominant and autosomal recessive PEO syn-
dromes [154^158], MNGIE [155,159], recurrent my-
oglobinuria [160], dilated or hypertrophic
cardiomyopathy [161,162], Wolfram syndrome
[163], sideroblastic anaemia [164] and in patients
with Parkinsonian-like features [153,154] or myopa-
thy alone [153]. Multiple deletions have even been
identi¢ed in one patient with MERRF [165]. Much
lower levels of multiple mtDNA deletions, often only
detectable by polymerase chain reaction ampli¢ca-
tion (PCR), have also been identi¢ed in muscle
from patients with inclusion body myositis [166]
and late onset mitochondrial myopathy [167] as
Table 5
Large-scale single mtDNA rearrangements
Defect Phenotype (inheritance) Ref.
Single deletion PEO syndromes (sporadic) [132,133]
KSS (sporadic) [132,133]
KSS+strokes (sporadic) [142,143]
Pearson’s syndrome (sporadic) [134]
Pearson’s syndrome to KSS (sporadic) [135]
Leigh’s syndrome þ Pearson’s syndrome (sporadic) [144]
MELAS (sporadic) [141]
Wolfram syndrome (sporadic) [138]
Ataxia leucodystrophy (sporadic) [139]
Infantile diarrhoea, villous atrophy (sporadic) [140]
Migraine and strokes (sporadic) [145]
Tandem duplication PEO+diabetes (maternal) [151]
KSS+diabetes (sporadic) [143,210]
PEO+multisystem disease (maternal) [150]
Deletion-duplication Diabetes+deafness (maternal) [137]
Infantile diarrhoea, villous atrophy (sporadic) [140]
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well as in various tissues from older individuals
[168,169].
Linkage studies in seven large pedigrees with au-
tosomal dominant PEO syndromes and multiple de-
letions have assigned the disease locus to chromo-
some 10q23.3^24.3 in one Finnish family [170] and
to chromosome 3p14.1^21.2 in three of six Italian
families [171]. The absence of linkage in three Italian
families indicates that the autosomal dominant forms
of PEO with multiple deletions exhibits considerable
genetic heterogeneity.
Tissue speci¢c depletion of apparently normal
mtDNA which has been identi¢ed in fatal infantile
and more benign childhood myopathies [172,173],
fatal infantile hepatopathy [174] and in early onset
encephalopathy [175,176] appears to conform to an
autosomal recessive trait again suggesting that the
primary defects reside in the nucleus [155]. Cell fu-
sion experiments using cultured ¢broblasts which
were found to express the depletion trait have pro-
vided some support for this hypothesis [177]. Deple-
tion of mtDNA, however, appears to be a tissue
speci¢c disorder and has not been expressed in ¢bro-
blast cultures from other cases [155]. A subsequent
study by the same group has shown that early pri-
mary myoblast cultures from another patient who
died of hepatopathy, had normal levels of mtDNA
despite the fact that the muscle from which the my-
oblasts were derived showed a 73% reduction in the
level of mtDNA [178]. Later passages and clonal
myoblast cultures, however, showed a progressive
decline in the level of mtDNA which was restored
when the mtDNA depleted mitochondria were trans-
ferred to a mtDNA-less (b0) cell line [178]. In anoth-
er study of a patient with mtDNA depletion in skel-
etal muscle, the levels of mtDNA in lymphocytes,
cultured ¢broblasts and myoblasts as well as in my-
otubes innervated in culture for up to four months
were indistinguishable from controls [176]. More-
over, myoblasts from this patient retained the ca-
pacity to restore mtDNA levels to normal after being
depleted of mtDNA by short term exposure to ethi-
dium bromide [176]. These ¢ndings would suggest
that the depletion trait is not due to a defect in the
resumption of mtDNA replication after formation of
the blastocyst as has been proposed [172], but is ex-
pressed only at a later stage of muscle di¡erentiation
[155,176,178]. Reduced cross-reacting material for
mitochondrial transcription factor A (mtTFA) a pro-
tein involved in mtDNA transcription and replica-
tion [179] as well as reduced levels of its transcript
(mtTFA mRNA) have been reported in muscle ex-
pressing the depletion trait but the changes could be
secondary to the very low levels of mtDNA [180].
Although mtTFA is essential for the maintenance
of mtDNA copy number, the ¢ndings in a recent
study of genetically engineered mice homozygous or
heterozygous for a knockout mtTFA allele would
suggest that de¢ciency of mtTFA is unlikely to be
the primary cause of tissue-speci¢c mtDNA deple-
tion syndromes in humans [181]. Mice heterozygous
for the knockout allele showed a 50% reduction in
mtTFA transcripts and protein and about a 40%
reduction in mtDNA copy number which was
present in all tissues examined [181]. Only the heart
muscle, however, showed signi¢cantly reduced activ-
ities of the respiratory enzyme complexes containing
mtDNA encoded subunits. Foetuses homozygous for
the mutant allele died before the 10th day of embry-
onic life with extensive developmental abnormalities
and absence of detectable mtDNA and COX activity
in all tissues [181].
6. Defects in nuclear genes
Disorders thought to be due to nuclear gene mu-
tations include the fatal and benign infantile myopa-
thies with primary COX de¢ciency [182], COX de¢-
cient Leigh’s syndrome [183] and rare but treatable
encephalomyopathies due to severe coenzyme Q10
de¢ciency [184,185]. To date, however, only two nu-
clear inborn errors of oxidative phosphorylation
have been identi¢ed at a molecular level [5,186].
The ¢rst of these involved a C-to-T transition at
nucleotide 1684 in the £avoprotein subunit gene of
Complex II, which was identi¢ed in two sisters with a
Leigh-type encephalopathy who were found to have
a severe de¢ciency of Complex II [5]. The second
nuclear gene mutation involved a 5-bp duplication
in the 18-kDa Complex I subunit gene which de-
stroyed a phosphorylation site in the carboxy termi-
nus of the 18-kDa protein [186]. It was identi¢ed in a
male infant with a rapidly progressive encephalop-
athy but normal lactate levels in the blood and cer-
ebrospinal £uid and a normal muscle biopsy [186].
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7. Discussion
The remarkable degree of clinical heterogeneity
associated with most of the more common mtDNA
mutations, as well as the continued discovery of new
mutations and new phenotypes has made it di⁄cult
to devise a rational classi¢cation of these diseases on
the basis of mtDNA analysis alone [187]. Most of the
distinctive syndromes such as KSS, MELAS,
MERRF and MNGIE as well as Leigh’s syndrome
and LHON have turned out to be genetically heter-
ogeneous and many of the mutations associated with
these disorders also occur with other phenotypes
which are clinically quite distinct. This is exempli¢ed
by the common MELAS 3243 mutation which ac-
counts for 80% of all MELAS cases but is also found
in sporadic and maternally inherited PEO syn-
dromes, maternally inherited diabetes mellitus and
in myopathy alone. Moreover, several individual
clinical manifestations such as dementia, cerebellar
ataxia, seizures, deafness and myopathy span a vari-
ety of di¡erent mtDNA abnormalities and even those
which are cardinal to the de¢nition of distinctive
syndromes such as PEO, myoclonus, pigmentary ret-
inopathy, strokes and gastrointestinal dysfunction
are not mutation speci¢c. As mitochondria are ubiq-
uitous, it might seem reasonable to assume that all
mtDNA mutations can a¡ect all tissues, but there are
a few exceptions which have so far stood the test of
time. Perhaps the most notable of these is the ab-
sence of major CNS disease in patients harbouring
one of the primary LHON mutations, even to the
extent of being virtually homoplasmic for the mutant
genome [38,39]. Although an MS-like illness has been
described in some a¡ected LHON females with the
11 778 or the 3460 transitions [36] and a severe and
sometimes fatal encephalopathy a¡ected several
members of a unique Queensland LHON pedigree
harbouring the 14 484 mutation [188,189], in the
overwhelming majority of cases, LHON appears to
be a highly tissue-speci¢c disease [39]. Autoimmune
mechanisms, possibly triggered by aberrant Complex
I proteins [190] have been invoked to explain the
MS-like illness and the unique Queensland LHON
pedigree was found to be homoplasmic for a second
mtDNA mutation, a T4160C transition in ND1,
which may have served to augment the severity of
the phenotype [188]. It is interesting that a branch of
this family which lacked CNS disease and expressed
a more typical LHON phenotype was also homo-
plasmic for another mutation in ND1 (A4136G)
which was thought to have acted as an intragenic
suppressor [188]. So-called secondary mutations in
mtDNA protein encoding genes have been reported
in other pedigrees with LHON but their role in dis-
ease pathogenesis is unclear as many of them occur
at low frequency in the normal population
[38,39,191].
Another notable exception to the notion that all
mtDNA mutations can a¡ect all tissues, is the appar-
ent absence of pigmentary retinopathy in patients
harbouring the common MERRF 8344 transition.
Degeneration of the retinal pigment epithelium has
been associated with several of the more common
mtDNA mutations and was a prominent feature in
the one reported patient with a G8313A transition in
the same tRNALys gene [72], but as far as we are
aware it has not been found in any patient with
MERRF 8344. Although the relative proportions
of mutant mtDNA in LHON brain and in MERRF
8344 retinal pigment epithelium are not known, their
presence at universally high levels in other tissues
would suggest that a given mtDNA mutation can
cause a defect in oxidative phosphorylation which
is manifest clinically in one type of cell population
but not in another, even when present in comparably
high amounts. With a di¡erent mtDNA mutation,
however, the situation may be reversed as has been
observed with allelic mutations in the same mito-
chondrial genes [27,54,55,72]. That this may be the
case is illustrated by a recent 31P magnetic resonance
spectroscopy study of LHON 11 778 skeletal muscle
which despite being una¡ected clinically showed an
abnormally low phosphorylation potential at rest
and a markedly reduced rate of phosphocreatine re-
synthesis after a period of exercise [192]. Similar, but
less severe changes were seen with the 14 484 LHON
mutation, but the ¢ndings in subjects with the 3460
LHON mutation were relatively normal [192]. The
mechanisms which determine whether or not a defect
in oxidative phosphorylation disrupts the functional
integrity of a cell population su⁄ciently to become
apparent clinically remain obscure, but the capacity
to eliminate reactive oxygens, which might further
impair the cell’s metabolic machinery, is one theoret-
ical possibility [193].
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Studies of cybrid clones harbouring mtDNA mu-
tations which alter (point mutations) or eliminate
(deletions) tRNA genes have shown that when the
proportion of mutant mtDNA reaches a certain crit-
ical threshold there is a rapid decline in the synthesis
of mtDNA encoded proteins and a corresponding
loss of respiratory chain activity [8^10,13,16,64,65].
Although variations in segregation behaviour and in
threshold have been observed with di¡erent donor or
recipient cells [16,64,65,194], the ultimate e¡ect of the
mtDNA mutation is translational failure. Decreased
stability and defective aminoacylation of the mutant
tRNA which results in premature translational ter-
mination are thought to be the mechanisms with the
common MERRF 8344 mutation [66] and a small
decrease in aminoacylation has also been reported
with the A4317G mutation in the mitochondrial
tRNAIle gene originally identi¢ed in fatal infantile
cardiomyopathy [195]. The molecular basis for trans-
lation failure with other tRNA mutations, however,
remains unknown but faulty processing of precursor
transcripts, altered post-transcriptional modi¢cation
and/or stability of the tRNA molecule or impaired
recognition by other components of the translational
machinery are some theoretical possibilities.
In addition to the mutation itself and its relative
abundance with respect to wild-type genomes, there
is growing evidence that a multiplicity of other fac-
tors are likely to be involved in determining pheno-
typic expression at a cellular level. Perhaps the most
important of these are the overall mtDNA copy
number [64,65,194], the mtDNA haplotype
[33,194,196], the distribution of mutant and wild-
type mtDNAs among the mitochondrial population
[64,65,194], the capacity for mitochondrial fusion
and for intramitochondrial complementation [197]
and the functional reserve or e⁄ciency of the mito-
chondrial translational machinery [198,199] as well as
the nuclear genetic background [64,194]. The impor-
tance of the nuclear genetic background was recently
demonstrated in lymphoblastoid cell lines derived
from members of an Arab-Israeli family with mater-
nally inherited non-syndromic deafness who har-
boured the A1555G mutation in the 12S rRNA
[35]. This study showed that the severity of mito-
chondrial dysfunction in lymphoblastoid cells homo-
plasmic for the mutation correlated with the presence
or absence of hearing loss in the donor individual
[35]. As predicted from studies of other families
with the 1555 mutation in which the deafness was
induced or enhanced by treatment with aminoglyco-
side [37,200], the lymphoblast cell lines from both
symptomatic and asymptomatic members of this
family were found to be markedly sensitive to amino-
glycosides when added to the culture medium [35].
At a clinical level the diversity of phenotypes is
thought to depend on variations in the degree of
mtDNA heteroplasmy in the di¡erent tissues and
on the threshold levels of mutant mtDNA required
to cause cellular or organ dysfunction [1,3]. The mul-
tiple factors which are likely to set the level of the
threshold e¡ect have already been discussed, but the
mechanisms which determine mtDNA heteroplasmy
are even more complex. In an individual who mater-
nally inherits a pathogenic mtDNA mutation, the
degree of mtDNA heteroplasmy in the tissues of
that individual is thought to be determined by the
dose of mutant mtDNA in the fertilised egg and the
way in which mutated and wild-type genomes repli-
cate and segregate during development. Replication
of mtDNA is regulated by nuclear genes, but mitotic
segregation is thought to occur by a stochastic or
random process [201,202]. However, in a recent study
of genetically engineered heteroplasmic mice carrying
two di¡erent mtDNA genotypes, there was evidence
for random genetic drift in some tissues but in liver,
kidney, spleen and blood there appeared to be strong
tissue-speci¢c selection for di¡erent mtDNA geno-
types in the same animal [203]. Another study of
mtDNA inheritance in the marine mussel Mytilus
edulis showed that in the male which normally har-
bours two distinct mtDNAs, both the replication and
the partitioning of mitochondrial genomes was selec-
tive for the speci¢c male mtDNA genotype [204].
Recent evidence also suggests that the nuclear genetic
background may determine the direction of mtDNA
segregation in cybrid clones, heteroplasmic for the
MELAS 3243 mutation [205]. These studies taken
together would suggest that replicative segregation
of mtDNA may not be stochastic as has been pre-
viously supposed [201,202] but may be determined by
a level of interaction between the two genomes, nu-
clear and mitochondrial, which may vary in di¡erent
tissues and may encompass genes not directly in-
volved in the formation and maintenance of the ox-
idative phosphorylation system [206]. In conjunction
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with other factors discussed earlier, such a mecha-
nism would help to unravel the enigma of geno-
type-phenotype associations and would, for example,
explain why di¡erent phenotypes associated with the
common MELAS 3243 mutation tend to segregate in
di¡erent pedigrees [18,19,78], and why they show dif-
ferences in the distribution of mutant mtDNAs in
their biopsied skeletal muscle ¢bres [207].
Despite breathtaking advances in the ¢eld of mi-
tochondrial medicine which have generated more
than 2000 original publications, it is still unclear
how MELAS 3243, one of the most common patho-
genic mtDNA mutations in humans, can cause dis-
eases as far apart clinically as a devastating and rap-
idly fatal encephalomyopathy in childhood or early
adolescence and benign non-progressive ptosis, non-
insulin dependent diabetes mellitus or exercise intol-
erance in late adult life.
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